Advances in the management of macular degeneration

F1000Prime Reports

Volumn 6, Issue , 2014, Pages

  Singer, Michael ^a  

^a Medical Center Ophthalmology Associates   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AL 78898A; ALEXION; BEVACIZUMAB; DOXYCYCLINE; ECULIZUMAB; EMIXUSTAT; GLADERMA; GLATIRAMER; PF 4382923; UNCLASSIFIED DRUG;

ARTICLE; COMPLEMENT INHIBITION; EXUDATIVE MACULAR DEGENERATION; GEOGRAPHIC ATROPHY; HUMAN; MEDICAL TECHNOLOGY; NEUROPROTECTION; RETINA MACULA AGE RELATED DEGENERATION; STEM CELL TRANSPLANTATION; VISUAL IMPAIRMENT;

EID: 84900561447     PISSN: None     EISSN: 20517599     Source Type: Journal    
DOI: 10.12703/P6-29     Document Type: Article

References (23)

1. AMD Alliance International. [http://www.amdalliance.org/]
2. Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY, Sy JP, Schneider S: ANCHOR Study Group: Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Eng J Med 2006, 355:1432-44. (Pubitemid 44511558)
3. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, Kim RY: MARINA Study Group. Ranibizumab for neovascular age related macular degeneration. N Engl J Med 2006, 355:14-1431.
4. Heier JS, Brown DM, Chong V, Korobelnik JF, Kaiser PK, Nguyen QD, Kirchhof B, Ho A, Ogura Y, Yancopoulos GD, Stahl N, Vitti R, Berliner AJ, Soo Y, Anderesi M, Groetzbach G, Sommerauer B, Sandbrink R, Simader C, Schmidt-Erfurth U: VIEW 1 and VIEW 2 Study Groups. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology 2012, 119:2537-48.
5. Comparison of Age-Related Macular Degeneration Treatments Trials (CATT) Research Group, Martin OF, Maguire MG: Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: Two-year results. Ophthalmology 2012, 119:1388-98.
6. Chakravarthy U, Harding SP, Rogers CA, Downes SM, Lotery AJ, Culliford LA, Reeves BC; IVAN study investigators: Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial. Lancet 2013, 382:1258-67.
7. Ophthotech Corporation. [www.ophthotech.com]
8. Dugel, PU: Phase 2b clinical trial of Fovista'" anti-PDGF therapy (1.5 mg) in patients with neovascular age-related macular degeneration (wet AMO) [abstract]. Presented at Retina Subspecialty Day at the American Academy of Ophthalmology Annual Meeting (AAO)10-13 Nov 2012, Chicago, IL.
9. Callanan, D: Designed Ankyrin Repeat Proteins (DARPins): Proof of Concept Study [abstract]. Presented at Retina Subspecialty Day at the American Academy of Ophthalmology Annual Meeting (AAO)16-19 Nov 2013, Louisiana, LA.
10. Ohr Pharmaceutical. [http://www.ohrpharmaceutical.com]
11. PanOptica, Inc. [http://www.panopticapharma.com]
12. Age-Related Eye Disease Study 2 Research Group: Lutein+ Zeaxanthin and Omega-3 Fatty Acids for Age- Related Macular Degeneration: The Age-Related Eye Disease 2 (AREDS) Randomized Clinical Trial. JAMA 2013, 309:2005-15.
13. NT 501 program. [http://www.Neurotechusa.com]
14. Kupperman BD: Drug Delivery Implants for Geographic Atrophy. Retina today May 2012. [http://bmctoday.net/retinatoday/2012/05/article.asp?f=drug-delivery- implants-for-geographic-atrophy]
15. Roe R, Boyer D: The Pipeline for Dry macular Degeneration. Review of Ophthalmology 2011. [http://www.revophth.com/content/d/retinal-insider/i/1709/c/ 31319/]
16. Ding J, Lin J, Mace BE, Herrmann R, Sullivan P, Bowes Rickman C: Targeting age-related macular degeneration with Alzheimer's disease based immunotherapies: anti-amyloid-beta antibody attenuates pathologies in an age-related macular degeneration mouse model. Vision Res 2008, 48:339-45. (Pubitemid 351179512)
17. Evans JB, Syned BA: New hope for dry AMD? Nat Rev Drug Discov 2013, 12:501-2.
18. Chioy G: Is Dry AMD Treatable? Retina Today May 2012. [http://bmctoday.net/retinatoday/2012/05/article.asp?f=is-dry-amd-treatable]
19. Ambati J, Atkinson J, Gelfand B: Immunology of age realted macular degeneration. Nat Rev Immunol 2013, 13:438-51.
20. Hetwick, C: MAHALO Finds New Biomarker for Dry Macular Degeneration, Medscape Medical News 21 Nov 2013. [http://www.medscape.com/viewarticle/814822]
21. Mata NL, Lichter JB, Vogel R, Han Y, Bui TV, Singerman LJ: Investigation of oral fenretinide for treatment of geographic atrophy in age-related macular degeneration. Retina 2013, 33:498-507.
22. Mata, NL, Kubota R, Schneider S, Kissner J, Birch DG, Dugel PU: Pharmacodynamics Of Visual Cycle Modulation In the Treatment of GA, Emerging data from clinical studies demonstrate the biological activity of emixustat in the retina. Retinal Physician 2003. [http://www.retinalphysician.com/ articleviewer.aspx?articleID=108861]
23. Kubota R, Boman NL, David R, Mallikaarjun S, Patil S, Birch D: Safety and effect on rod function of ACU-4429, a novel small-molecule visual cycle modulator. Retina 2012, 32:183-8.